Leerink Partners started coverage on shares of Freenome (NASDAQ:FRNM – Free Report) in a research report report published on Friday, MarketBeat reports. The firm issued an outperform rating and a $18.00 price objective on the stock.
Freenome Stock Down 0.4%
NASDAQ:FRNM opened at $11.56 on Friday. Freenome has a 12 month low of $9.97 and a 12 month high of $14.26.
About Freenome
Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.
Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.
Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.
See Also
- Five stocks we like better than Freenome
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Freenome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freenome and related companies with MarketBeat.com's FREE daily email newsletter.
